oncopeptides - Robuta Search

https://oncopeptides.com/science/clinical-program/ Clinical Program - Oncopeptides The purpose of our melflufen clinical development program is to support regulatory approval processes globally and explore safe and effective use in different clinical program oncopeptides https://oncopeptides.com/press-releases/oncopeptides-ab-number-of-shares-and-votes-in-oncopeptides-13/ Oncopeptides AB: Number of shares and votes in Oncopeptides - Oncopeptides Stockholm - 31 July 2019 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announces that the number of shares and votes in Oncopeptides has changed as a number of shares oncopeptides ab votes https://oncopeptides.com/press-releases/oncopeptides-has-appointed-a-clinical-advisory-board-consisting-of-internationally-recognized-researchers-within-clinical-development-in-hematology/ Oncopeptides has appointed a Clinical Advisory Board consisting of internationally recognized... Stockholm - April 23 2018 - Oncopeptides AB (Nasdaq Stockholm, ONCO) today announced that the company has appointed a Clinical Advisory Board. The aim is to clinical advisory board oncopeptides appointed https://oncopeptides.com/news/oncopeptides-publishes-article-in-the-journal-of-clinical-pharmacology/ Oncopeptides publishes article in the Journal of Clinical Pharmacology - Oncopeptides October 23, 2023. A new article on the Phamacokinetics and metabolism of melflufen, marketed in Europe as Pepaxti, in patients with Relapsed Refractory... the journal oncopeptides publishes article clinical https://oncopeptides.com/press-releases/oncopeptides-ab-oncopeptides-has-completed-a-directed-share-issue-raising-approximately-sek-1106-million-usd-130-million/ Oncopeptides AB: Oncopeptides has completed a directed share issue raising approximately SEK 1,106... NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG https://oncopeptides.com/press-releases/oncopeptides-announces-final-terms-for-the-fully-guaranteed-rights-issue/ Oncopeptides announces final terms for the fully guaranteed rights issue - Oncopeptides THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND,... for the oncopeptides announces final terms https://oncopeptides.com/press-releases/oncopeptides-ab-oncopeptides-announces-26-overall-response-rate-of-melflufen-in-triple-class-refractory-multiple-myeloma-patients-from-the-pivotal-horizon-study/ Oncopeptides AB: Oncopeptides announces 26% Overall Response Rate of melflufen in triple-class... STOCKHOLM - March 26, 2020 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today the final topline results from the pivotal phase 2 HORIZON study response rate https://oncopeptides.com/press-releases/oncopeptides-ab-oncopeptides-announces-acceptance-of-four-abstracts-highlighting-melflufen-clinical-programs-for-presentation-at-24th-eha-congress-in-june-2019/ Oncopeptides AB: Oncopeptides Announces Acceptance of Four Abstracts Highlighting Melflufen... Stockholm - May 16, 2019 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that a total of four abstracts have been accepted for presentation at the oncopeptides ab announces acceptance four https://www.biospace.com/oncopeptides-selects-lore-io-s-life-sciences-cloud-analytics-solution-to-accelerate-commercialization-during-drug-pre-launch-phases Oncopeptides Selects Lore IO's Life Sciences Cloud Analytics Solution to Accelerate... Dec 8, 2020 - Lore IO's Common Data Model Expedites the Onboarding and Transformation of Vendor Data Sources for Pharmaceutical Companies life sciences cloud https://oncopeptides.com/press-releases/results-of-placing-in-oncopeptides-ab/ Results of Placing in Oncopeptides AB - Oncopeptides NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA. results of placing oncopeptides ab https://oncopeptides.com/press-releases/oncopeptides-ab-oncopeptides-presents-new-clinical-and-preclinical-melflufen-data-at-the-upcoming-european-hematology-association-meeting/ Oncopeptides AB: Oncopeptides presents new clinical and preclinical melflufen data at the upcoming... STOCKHOLM - May 12, 2021 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for https://oncopeptides.com/press-releases/oncopeptides-ab-oncopeptides-publishes-q1-report-2022/ Oncopeptides AB: Oncopeptides publishes Q1 report 2022 - Oncopeptides STOCKHOLM - May 4, 2022 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for oncopeptides ab publishes report https://oncopeptides.com/sv/pressmeddelanden/ Pressmeddelanden - Oncopeptides Pressmeddelanden Archive - Oncopeptides pressmeddelanden oncopeptides https://oncopeptides.com/press-releases/oncopeptides-ab-oncopeptides-strengthens-its-corporate-communications-function-by-appointing-rolf-gulliksen-as-global-head-of-corporate-communications/ Oncopeptides AB: Oncopeptides strengthens its corporate communications function by appointing Rolf... STOCKHOLM - April 2, 2020 - Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that Rolf Gulliksen has been appointed global head of corporate corporate communications oncopeptides ab function rolf https://oncopeptides.com/press-releases/oncopeptides-ab-invitation-to-webcast-for-presentation-of-ocean-data-presented-at-imw/ Oncopeptides AB: Invitation to webcast for presentation of OCEAN data presented at IMW -... STOCKHOLM - September 9, 2021 - Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for https://oncopeptides.com/news/oncopeptides-selected-to-present-additional-data-from-ocean-study-at-the-american-society-of-hematology-meeting/ Oncopeptides selected to present additional data from OCEAN study at the American Society of... November 13, 2023. Long-term outcomes from its Phase 3 OCEAN study has been accepted as a poster and will be presented at ASH in San Diego, December 9-12. https://oncopeptides.com/press-releases/oncopeptides-publishes-disclosure-document-regarding-rights-issue/ Oncopeptides publishes disclosure document regarding rights issue - Oncopeptides THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONG KONG, ISRAEL, JAPAN, CANADA, NEW... oncopeptides publishes disclosure document regarding